Skip to content
Home/GPs/Cambridge Innovation Capital
Cambridge Innovation Capital

Cambridge Innovation Capital

Cambridge, United Kingdom·Founded 2013··cic.vc

Cambridge Innovation Capital is a Cambridge deep-tech and life-sciences venture firm founded in 2013 to back University of Cambridge ecosystem spin-outs, typically at Series A. It launched in 2013 with GBP 50 million from Invesco Perpetual, Lansdowne Partners, the Cambridge University Endowment Fund, ARM and IP Group, grew its first vehicle to GBP 275 million, closed Fund II at GBP 225 million (USD 300 million) in April 2022, and launched a GBP 100 million Opportunity Fund in February 2025 anchored by Aviva Investors and British Patient Capital. The operating company is Cambridge Innovation Capital Limited (Companies House number 08243718) and its manager, Cambridge Innovation Capital Manager Limited, is authorised and regulated by the UK Financial Conduct Authority under firm reference number 918898.

AUM
€702M
Funds
4
vintages 2013–2025
Portfolio
23
Exits
9
SectorsHealthcareTMTSoftware

Key facts

HQCambridge, United Kingdom
Founded2013
Websitecic.vc

Recent exits

Seldon
AI/ML · 2026 · 6yr hold
Congenica
Biotech · 2025 · 10yr hold
Cytora
InsurTech · 2025 · 8yr hold
PredictImmune
HealthTech · 2024 · 5yr hold

Coverage notes

4 funds tracked, 32 portfolio companies (23 active · 9 realized). Verified weekly from public filings and deal announcements.

Funds & portfolio

Every fund Cambridge Innovation Capital has raised, with its portfolio companies. Hand-checked from public filings.

4 funds
CIC Opportunity FundVC
2025 · 1yr€100M2 active

Unrealized

2 held
AI/MLUK· Entry 2026
Trent AIActive
AI/MLUK· Entry 2026
CIC Fund IIIVC
2025 · 1yr€293M0 active

No portfolio companies tracked yet.

CIC Fund IIVC
2022 · 4yr€263M12 active · 2 realized

Unrealized

12 held
Deep TechUK· Entry 2022
BiotechUK· Entry 2023
EpitopeaActive
BiotechUK· Entry 2022
TelecomUK· Entry 2024
ImmutrinActive
BiotechUK· Entry 2025
Mosaic TXActive
BiotechUK· Entry 2023
NucleraActive
BiotechUnited Kingdom· Entry 2024
BiotechUSA· Entry 2022
Deep TechUK· Entry 2022
BiotechUK· Entry 2023
BiotechUK· Entry 2025
AI/MLUK· Entry 2022

Realized

2 exits
CongenicaExited 2025
BiotechUK· Entry 2015
Trade Saleto
PetMedixExited 2023
BiotechUnited Kingdom· Entry 2020
Trade Saleto
CIC Fund IVC
2013 · 13yr€322M9 active · 7 realized

Unrealized

9 held
BiotechUK· Entry 2016
BiotechUK· Entry 2016
MedTechUK· Entry 2016
BiotechUK· Entry 2016
Deep TechUK· Entry 2014
RiverlaneActive
Deep TechUK· Entry 2017
AI/MLUK· Entry 2017
MedTechUK· Entry 2019
BiotechUK· Entry 2016

Realized

7 exits
AbcodiaExited 2022
HealthTechUK· Entry 2015
Trade Saleto
Audio AnalyticExited 2022
AI/MLUK· Entry 2017
Trade Saleto
CytoraExited 2025
InsurTechUK· Entry 2017
Trade Saleto
BiotechUK· Entry 2019
Trade Saleto
InivataExited 2021
HealthTechUK· Entry 2016
Trade Saleto
PredictImmuneExited 2024
HealthTechUK· Entry 2019
Liquidation
SeldonExited 2026
AI/MLUK· Entry 2020
Liquidation
Track Cambridge Innovation Capital

Saved GPs appear in your watchlist, one click from your workspace.

About Cambridge Innovation Capital

Cambridge Innovation Capital (CIC) is a UK preferred venture capital investor for the University of Cambridge ecosystem with approximately £600 million of assets under management as of December 2024, headquartered in Cambridge. The firm was founded in 2013 as the strategic partner of the University of Cambridge, anchored in the Cambridge cluster spinout pipeline. CIC remains a partner-owned independent VC platform with exclusive scale-up investor status across Cambridge spinouts.

Investment thesis

CIC deploys capital through three plus active vehicles (Fund I, Fund II, Fund III early-stage £250 million 2025 plus £100 million Opportunity Fund 2025), targeting early-stage and growth venture investments in deep-tech and life sciences spinouts from the Cambridge cluster. The Opportunity Fund enables late-stage follow-ons up to £20 million per round, addressing the UK growth-financing gap that historically constrained Cambridge spinout scale-up. Sector focus spans artificial intelligence, quantum computing, semiconductors, therapeutics, medtech and diagnostics, digital health and genomics. Geographic deployment is anchored on Cambridge ecosystem with broader UK reach.

Recent activity

Recent investments include Pragmatic Semiconductor (chips, 2025), Riverlane (quantum computing, 2024-2025) and commitments to multiple Cambridge spinouts under Fund III (2025). Realised exits across the 2024-2025 period emphasised follow-on rounds over secondary realisations, with gene therapy and biotech exits forming the historical baseline. The platform continues active deployment across the Cambridge spinout pipeline and Opportunity Fund late-stage strategy. Detailed buyer names and multiple data available on Pro at €29/month.

Last updated June 2026 · Sourced from public filings